Toshiba Appoints Rance M. Poehler as President & Chief Executive Officer for Retail Solutions Business
16.11.2020 19:00:00 EET | Business Wire | Press release
Toshiba Global Commerce Solutions today announced Rance M. Poehler is joining the company as its new President and Chief Executive Officer effective November 16, 2020. Poehler has more than 25 years of experience building and expanding business-to-business organizations in unique vertical markets including retail where he has led the development of end-to-end solutions for general retail, quick-service restaurant, hospitality, and other segments. In his role, he will be responsible for leading the company’s continued transformation as a trusted retail commerce solutions leader for its large and growing customer and partner community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005083/en/
Rance M. Poehle, President & CEO, Toshiba Global Commerce Solutions (Photo: Business Wire)
Poehler replaces Scott Maccabe who had been appointed President & CEO since 2015. Maccabe is retiring from his role as President & CEO at Toshiba Global Commerce Solutions, while he remains in this capacity at Toshiba America Business Solutions. Poehler takes over effective immediately and will work closely with Maccabe to ensure a full and seamless transition of duties. We thank Scott Maccabe for his commitment, strong leadership and many contributions to the success and growth of the business.
“Rance Poehler is a highly accomplished business executive with a proven track-record for scaling businesses that are in a unique position to transform the industries they serve,” said Maccabe. “Rance brings the fortitude and execution prowess needed to transition the retail business to a full-fledged strategic partner for both customers and partners.”
Poehler joins Toshiba with extensive retail commerce solutions experience and insight. During his tenure as President of Panasonic Systems Communications Company of North America he led a $1.1 billion division morphing it from a product-centric organization to an end-to-end provider of innovative retail solutions in the areas of mobility, point-of-sale, digital signage, computer vision, and analytics that helped Fortune 1000 companies understand shopper demographics and behavior, improve associate engagement and create better customer experiences. While at Dell Technologies he served as vice president of worldwide sales for its cloud client computing team that represents a full suite of cloud and desktop virtualization solutions for retail that enabled scalable thin client solutions. Poehler’s experience also includes Pivot3 where he served as Chief Revenue Officer responsible for leading the global sales organization and executing on the company’s growth strategy and talent acquisition as they developed and went to market with a hyper-converged software platform that manages mixed workloads including IOT-surveillance, analytics, and hybrid cloud solutions.
“The retail industry is looking for new and innovative ways to adapt more quickly to customer needs while they optimize store operations and reduce the cost of delivering and managing their business. Toshiba has a strong worldwide retail position and is on the verge of disrupting the industry with their intelligent end-to-end solutions,” said Poehler. “I’m honored and excited about the opportunity to help this world-class retail commerce solutions business grow in ways that support our partner community, and helps our clients delight their customers while becoming even greater merchants.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for integrated in-store solutions. Together with a global team of dedicated business partners, we achieve brilliant commerce by advancing the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter, LinkedIn, Facebook and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005083/en/
Contact information
Fredrik Carlegren
Vice President of Marketing
(984) 444-2769
fcarlegren@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom